Conference Proceedings
First-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA
M Reck, T-E Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, E Richardet, J Bennouna, Y Cheng, L Paz-Ares, S Lu, T John, B Padilla, X Sun, A Moisei, J Yan, Y Yuan, SI Blum, DP Carbone
ANNALS OF ONCOLOGY | ELSEVIER | Published : 2020
Grants
Funding Acknowledgements
Bristol-Myers Squibb Company.